Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBIT Margin (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EBIT Margin for 4 consecutive years, with 285.07% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 40255.0% to 285.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 31.32%, a 20960.0% increase, with the full-year FY2025 number at 31.32%, up 20960.0% from a year prior.
  • EBIT Margin was 285.07% for Q4 2025 at Iovance Biotherapeutics, up from 140.69% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 285.07% in Q4 2025 to a low of 46254.62% in Q2 2023.
  • A 3-year average of 10447.88% and a median of 245.76% in 2025 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: surged 4592699bps in 2024, then skyrocketed 1142bps in 2025.
  • Iovance Biotherapeutics' EBIT Margin stood at 25156.85% in 2023, then skyrocketed by 100bps to 117.48% in 2024, then soared by 343bps to 285.07% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EBIT Margin are 285.07% (Q4 2025), 140.69% (Q3 2025), and 189.78% (Q2 2025).